Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA) versus AAP+APA in patients with advanced prostate cancer with noncastrate testosterone levels: (LACOG 0415)

01/05/2020

Articles, Publications, Publications Genitourinary

Fernando C. Maluf, Andre P. Fay, Vinícius Carrera Souza, Fabio A. B. Schutz, Oren Smaletz, Daniel Herchenhorn, Vanessa Fabricio, Rosemarie Gidekel, Eduardo Cronemberger, Murilo Luz, Suelen P. S. Martins, David Queiroz Borges Muniz, Fabio Andre Franke, Fabio Peixoto, Flavio Mavignier Carcano, Andrea Juliana Gomes, Felipe Cruz, Rafaela Gomes, Paulo Ricardo Santos Nunes Filho, Gustavo Werutsky

DOI: 10.1200/JCO.2020.38.15_suppl.5505

Full link: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5505

Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA) versus AAP+APA in patients with advanced prostate cancer with noncastrate testosterone levels: (LACOG 0415)

Send us a message

Cura Project

Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA) versus AAP+APA in patients with advanced prostate cancer with noncastrate testosterone levels: (LACOG 0415)

Related Posts

A study to observe patients characteristics, tratments patterns and outcomes in patients with newly diagnosed breast cancer in Latin America – LATINA Breast (LACOG 0615/ MO39485)

Influence of physician’s lifestyle on the prescription of healthy habits to breast cancer patients (LACOG 1218)

The socioeconomic impact of breast cancer in Brazil: An analysis of AMAZONA III cohort study

Health-related quality of life outcomes in head and neck cancer: results from a prospective, real-world data study with Brazilian patients treated with intensity modulated radiation therapy, conformal and conventional radiation techniques